Home/ReGenX Biosciences/Curran Simpson
CS

Curran Simpson

Chief Operating Officer

ReGenX Biosciences

ReGenX Biosciences Pipeline

DrugIndicationPhase
RGX-121Mucopolysaccharidosis Type II (MPS II, Hunter syndrome)Phase 2/3
RGX-314Wet Age-Related Macular Degeneration (AMD)Phase 2/3
RGX-202Duchenne Muscular Dystrophy (DMD)Phase 1/2
RGX-381Ocular Manifestations of Fabry DiseasePreclinical